The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

The proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily,
is one of the most extensively studied ligand-inducible transcription factors. Since its …

Although substantial progress has been made in cancer biology and treatment, clinical
outcomes of bladder carcinoma (BC) patients are still not satisfactory. The tumor …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with
heterogeneous clinical outcomes. Several molecular classifications have been proposed …

Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

Background FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed
phenotype and has therefore been postulated to be less responsive to immune checkpoint …

Although immune checkpoint blockade (ICB) therapies have been approved for bladder
cancer (BLCA), only a minority of patients respond to these therapies, and there is an urgent …